Notably, FBXW7 is commonly rendered inactive by mutations, deletions, or promoter hypermethylation in some neoplasms, including hematologic malignancies, breast, colon, uterine, and lung cancer (Zhao et al., 2010; King et al., 2013; Yokobori et al., 2014; Kothari et al., 2016; Xiao et al., 2018; Cuevas et al., 2019). Here, FBXW7 is linked to neoplasm.